Haemonetics (STU:HAZ) Marketable Securities: €0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HAZ Haemonetics Corp STU:HAZ
30 GF Score
Price €73.50
GF Value €73.45
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Haemonetics Marketable Securities?

Haemonetics STU:HAZ 30 Marketable Securities is €0 Mil as of Mar. 2026. GuruFocus rates STU:HAZ with a GF Score™ of 30/100 and a GF Value™ of €73.45 (Fairly Valued). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Haemonetics's Marketable Securities for the quarter that ended in Mar. 2026 was €0 Mil.

Haemonetics  (STU:HAZ) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Haemonetics Marketable Securities Related Terms

Haemonetics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Haemonetics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Marketable Securities Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Haemonetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:HAZ
30GF Score
Haemonetics Corp STU:HAZ
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haemonetics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0 Mil mean?
Haemonetics (STU:HAZ) has a Marketable Securities of €0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Haemonetics and its competitors.
Is Haemonetics' Marketable Securities too high?
Haemonetics' current Marketable Securities is €0 Mil. Overall, Haemonetics has a GF Score™ of 30/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Marketable Securities compare to IRTC and ITGR?
Haemonetics' Marketable Securities of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Haemonetics and its competitors. Haemonetics's current Marketable Securities is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (STU:HAZ) is currently considered Fairly Valued. The stock's GF Value™ is €73.45, compared to a current price of €73.50 — trading 0.1% above its estimated fair value. The current Marketable Securities is €0 Mil. Haemonetics' overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Marketable Securities is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be overvalued. The current stock price of €73.50 is trading 0.1% above its estimated GF Value™ of €73.45. GuruFocus considers Haemonetics to be Fairly Valued.

Key valuation signals for STU:HAZ:

  • Marketable Securities: €0 Mil
  • GF Value™: €73.45 vs. price of €73.50 (0.1% above fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
30GF Score

Get the complete analysis for STU:HAZ

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.50
Price
€73.45
GF Value